shop
Investors
View our Gastro-Mint® product for the relief of symptoms of medically diagnosed Irritable Bowel Syndrome.
November 20, 2025
AFT Pharmaceuticals (NZX: AFT, ASX: AFP) today reports a strong first-half performance for the six months to 30 September 2025, with revenue growing 3…
September 25, 2025
– Sales tracking in line with $300 million FY27 revenue target – Clinical trial supports the potential patient benefits of novel iron IV development …
April 24, 2024
AFT collaborate with Massey Ventures and Gilles McIndoe to begin the development of a topical treatment for keloid and hypertrophic scarring….
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Google reCAPTCHA helps protect websites from spam and abuse by verifying user interactions through challenges.